Hisamitsu Pharmaceutical Co., Inc. (HTSUF)

Market Cap	2.14B
Revenue (ttm)	1.04B
Net Income (ttm)	144.77M
Shares Out	n/a
EPS (ttm)	1.96
PE Ratio	14.80
Forward PE	n/a
Dividend	0.61 (2.11%)
Ex-Dividend Date	Feb 27, 2025

Volume	1
Average Volume	6
Open	33.01
Previous Close	28.94
Day's Range	33.01 - 33.01
52-Week Range	24.56 - 33.01
Beta	0.42
RSI	14.39
Earnings Date	Jul 10, 2025

About HTSUF

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete′s foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United St...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1847
• Employees: 2,799
• Stock Exchange: OTCMKTS
• Ticker Symbol: HTSUF

Financial Performance

In 2024, HTSUF's revenue was 156.01 billion, an increase of 10.09% compared to the previous year's 141.71 billion. Earnings were 21.76 billion, an increase of 55.76%.

Financial numbers in JPY